Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis - The Predictive Value of Exercise Capacity and Gas Exchange Efficiency

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Gläser, Sven ^a   Obst, Anne ^a   Koch, Beate ^a   Henkel, Beate ^a   Grieger, Anita ^a   Felix, Stephan B ^a   Halank, Michael ^b   Bruch, Leonhard ^c   Bollmann, Tom ^a   Warnke, Christian ^a   Schäper, Christoph ^a   Ewert, Ralf ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c Trauma Hospital Berlin   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE; OXYGEN;

ADULT; AGED; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CLINICAL EVALUATION; EXERCISE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG GAS EXCHANGE; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXYGEN CONSUMPTION; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PULMONARY HYPERTENSION; SURVIVAL;

AGED; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IDIOPATHIC PULMONARY FIBROSIS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PULMONARY GAS EXCHANGE;

EID: 84879274777     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065643     Document Type: Article

References (33)

1. Tzilas V, Koti A, Papandrinopoulou D, Tsoukalas G, (2009) Prognostic factors in idiopathic pulmonary fibrosis. Am J Med Sci 338: 481-485.
2. Ley B, Collard HR, King TE Jr, (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183: 431-440.
3. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, et al. (2005) Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 128: 2393-2399.
4. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD, (2007) Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 30: 715-721.
5. Kimura M, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, et al. (2012) Pulmonary Hypertension as a Prognostic Indicator at the Initial Evaluation in Idiopathic Pulmonary Fibrosis. Respiration.
6. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF, (2006) Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 129: 746-752.
7. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, et al. (2011) Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184: 459-466.
8. Glaser S, Noga O, Koch B, Opitz CF, Schmidt B, et al. (2009) Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med 103: 317-324.
9. Boutou AK, Pitsiou GG, Trigonis I, Papakosta D, Kontou PK, et al. (2011) Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension. Respirology 16: 451-458.
10. Papakosta D, Pitsiou G, Daniil Z, Dimadi M, Stagaki E, et al. (2011) Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters. Lung 189: 391-399.
11. Minai OA, Santacruz JF, Alster JM, Budev MM, McCarthy K, (2012) Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. Respir Med 106: 1613-1621.
12. Nathan SD, Shlobin OA, Barnett SD, Saggar R, Belperio JA, et al. (2008) Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 102: 1305-1310.
13. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, et al. (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824.
14. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34: 1219-1263.
15. Criee CP, Sorichter S, Smith HJ, Kardos P, Merget R, et al. (2011) Body plethysmography-its principles and clinical use. Respir Med 105: 959-971.
16. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. (2005) Standardisation of spirometry. Eur Respir J 26: 319-338.
17. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, et al. (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26: 720-735.
18. Nelson SB, Gardner RM, Crapo RO, Jensen RL, (1990) Performance evaluation of contemporary spirometers. Chest 97: 288-297.
19. Jones NL, Makrides L, Hitchcock C, Chypchar T, McCartney N, (1985) Normal standards for an incremental progressive cycle ergometer test. Am Rev Respir Dis 131: 700-708.
20. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 167: 211-277.
21. Palange P, Ward SA, Carlsen KH, Casaburi R, Gallagher CG, et al. (2007) Recommendations on the use of exercise testing in clinical practice. Eur Respir J 29: 185-209.
22. Wasserman K, Hansen JE, Sue DY, Stringer WW, Whipp BJ (2004) Principles of Exercise Testing and Interpretation: Including Pathophysiology and Clinical Applications.: Lippincott Williams and Wilkins.
23. Koch B, Schaper C, Ewert R, Volzke H, Obst A, et al. (2010) Lung function reference values in different German populations. Respir Med 105: 352-362.
24. Hansen JE, editor(2011) Pulmonary function testing and interpretation. First Edition ed. New Delhi: Jaypee Brothers Medical Publishers.
25. Glaser S, Ittermann T, Koch B, Volzke H, Wallaschofski H, et al. (2012) Airflow limitation, lung volumes and systemic inflammation in a general population. Eur Respir J 39: 29-37.
26. Glaser S, Schaper C, Ewert R, Koch B, Volzke H, et al. (2009) Beta-blocker and exercise capacity: an always relevant interference? Med Sci Sports Exerc 41: 967; author reply 968.
27. Koch B, Schaper C, Ittermann T, Spielhagen T, Dorr M, et al. (2009) Reference values for cardiopulmonary exercise testing in healthy volunteers: the SHIP study. Eur Respir J 33: 389-397.
28. Wasserman K, Hansen JE, Sue DY, Stringer WW, Sietsema KE, et al. (2012) Principles of exercise testing and interpretation: including pathophysiology and clinical applications. Philadelphia: Lippincott Williams and Wilkins, a Wolter Kluwer business.
29. Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, et al. (2009) The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 179: 402-407.
30. Shorr AF, Davies DB, Nathan SD, (2003) Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 124: 922-928.
31. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, et al. (2004) Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25: 2243-2278.
32. King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, et al. (2009) Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374: 222-228.
33. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, et al. (2004) A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350: 125-133.